Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression

Bolcont and colleagues frame the study around a growing interest in N,N-dimethyltryptamine (DMT) as a fast-acting psychedelic intervention for treatment-resistant depression, while noting that earlier work has focused mainly on symptom relief rather than broader recovery outcomes. The authors argue that anxiety, life satisfaction, and quality of life are important dimensions of wellbeing that may better capture the lived impact of treatment, but these outcomes have been underexplored for inhaled DMT, especially across both healthy individuals and patients with depression. The study set out to examine whether inhaled DMT, given with psychological support, is associated with sustained changes in state anxiety, life satisfaction, and quality of life. The researchers specifically wanted to see whether effects extend beyond acute symptom reduction, and whether they differ between healthy volunteers and patients with treatment-resistant depression. The paper presents this as an exploratory analysis intended to broaden the therapeutic profile of DMT and assess whether it may support recovery in multidimensional terms.

This paper reports an exploratory secondary analysis of data from two previously published open-label clinical trials. One was a Phase I trial in healthy volunteers designed originally to assess safety, tolerability, and dose optimisation. The other was a Phase IIa trial in patients with treatment-resistant depression designed originally to examine antidepressant effects. The researchers did not perform a formal pooled analysis because the two trials differed in design and follow-up structure; instead, they analysed them separately. Healthy participants were aged 21-60 years and underwent medical and psychiatric screening before enrolment. Twenty-seven healthy volunteers were recruited, although two were excluded from the analysis because of unsatisfactory inhalation, leaving 25 for analysis. Patients were aged 18-60 years, had a moderate to severe depressive episode lasting at least 4 weeks, and had failed to achieve remission with at least two antidepressants; diagnosis was confirmed using psychiatric evaluation and the Mini International Neuropsychiatric Interview. Fourteen patients were enrolled. Exclusion criteria included bipolar disorder, psychotic disorders, and other relevant medical conditions. Patients continued their usual pharmacological treatment during the study, apart from specified discontinuation of lithium and monoamine oxidase inhibitors before dosing. Both samples received inhaled purified DMT freebase derived from Mimosa tenuiflora. In the healthy trial, five dosing schemes were used in a fixed order: 5/20 mg, 7.5/30 mg, 10/40 mg, 12.5/50 mg, and 15/60 mg, with a lower dose in session 1 followed by a higher dose in session 2. In the patient trial, the fixed dosing scheme was 15/60 mg. DMT was administered in a supportive clinical setting with preparation meetings, psychologist-guided integration, music during sessions, and support from a psychiatrist and psychologist. Outcomes included state anxiety measured with the State-Trait Anxiety Inventory-State version, life satisfaction measured with the Satisfaction with Life Scale, and quality of life measured with the WHOQOL-BREF and WHOQOL-SRPB. The researchers also examined correlations with previously reported psychedelic experience measures and, in patients, with depression outcomes. Assessments occurred at baseline and at multiple follow-up points up to 12 months in patients, with timing not identical across the two trials. Analyses used linear mixed models with a Toeplitz covariance structure, with time and, for quality-of-life measures, domain as within-subject factors; dose was a between-subject factor in healthy volunteers. Missing data were handled using restricted maximum-likelihood estimation, post hoc comparisons were adjusted with Bonferroni correction, and effect sizes were reported as Cohen's d.

All participants completed both dosing sessions, but some follow-up data were missing. In the healthy group, two people were excluded from analysis, and a small number of questionnaire time points were incomplete. In the patient group, two participants did not complete the 12-month assessment. The healthy sample had a mean age of 30.3 years and the patient sample a mean age of 35.2 years; both samples were described as predominantly White or mixed ethnicity, highly educated, single, and unaffiliated with religion. For anxiety, both groups showed significant reductions in self-reported state anxiety over time. In healthy volunteers, STAI-S scores fell from baseline to the first and second dosing sessions and remained lower at day 1 after dosing, with no dose effect or time-by-dose interaction. In patients, STAI-S also declined significantly from baseline to the second dosing session and day 1. The decrease at 12 months in patients was not statistically significant, although the mean score appeared lower than baseline. For life satisfaction, healthy volunteers showed increases from baseline at day 1, day 7, and day 14, again without dose effects. In patients, life satisfaction improved over time, with a statistically significant increase from baseline to 12 months. Quality-of-life findings differed by group. Healthy volunteers showed no significant change on WHOQOL-BREF or WHOQOL-SRPB across time, dose, or domain. In patients, WHOQOL-BREF improved significantly over time, with increases from baseline at day 14, month 1, month 3, and month 12 across domains including physical health, psychological health, social relationships, and environment. WHOQOL-SRPB also improved over time in patients, with increases from baseline at day 14 and month 12. Domain-specific effects were seen for Inner Peace at day 14 and for Hope & Optimism at day 14 and month 12. Correlational analyses found no associations that survived correction for multiple comparisons between psychedelic experience ratings and changes in anxiety, life satisfaction, or quality of life. In patients, there was one uncorrected positive correlation between early reductions in anxiety and reductions in PHQ-9 depression scores from baseline to day 1, suggesting that early anxiety improvement may have tracked with concurrent mood improvement.

The authors interpret the findings as exploratory evidence that inhaled DMT combined with psychological support may influence wellbeing beyond depressive symptom reduction. They emphasise that the intervention was associated with short-term reductions in state anxiety in both healthy volunteers and patients with treatment-resistant depression, short-term gains in life satisfaction in healthy volunteers, and longer-term improvements in life satisfaction and quality of life in patients. They present these results as suggesting that DMT may support broader psychological and existential recovery, not only rapid antidepressant effects. Bolcont and colleagues place the findings alongside earlier research on ayahuasca and psilocybin, which has reported improvements in anxiety, wellbeing, meaning, and quality of life. They suggest that the present results extend this literature by showing similar patterns with inhaled DMT despite its much shorter duration of action. They also argue that the benefits may depend not just on pharmacology, but on subjective meaning-making and integration after the session. The authors acknowledge several important limitations. The study was open-label and lacked a placebo control, so expectancy effects, regression to the mean, and natural illness course could not be ruled out. Because the intervention included preparation, guided sessions, integration, music, and expressive tasks, the pharmacological effects of DMT could not be disentangled from psychological support. The sample was small and selective, reducing generalisability and statistical power. The long-term follow-up, especially at 12 months, may also have been affected by attrition, self-selection, concurrent psychotherapy or medication changes, and other life events not measured in the analysis. They also note that the two underlying trials differed in follow-up schedules and dosing protocols, making this a complementary secondary analysis rather than a fully harmonised pooled trial. In terms of implications, the authors suggest that multidimensional outcomes such as life satisfaction and quality of life may be especially important in recovery-oriented psychiatry and public health, because symptom remission alone may not restore functioning or wellbeing. They mention potential relevance for health systems seeking scalable interventions, including Brazil's Unified Health System, but stress that more rigorous placebo-controlled, double-blind studies with larger samples are needed before stronger conclusions can be drawn.

The authors conclude that, in this exploratory open-label study, inhaled DMT combined with psychological support was associated with reduced anxiety in both healthy volunteers and patients with treatment-resistant depression, plus increased life satisfaction in healthy volunteers and longer-term improvements in life satisfaction and quality of life in patients. They state that these findings support the idea that psychedelic interventions may contribute to broader psychological functioning and recovery beyond conventional symptom-focused outcomes. They also call for larger, placebo-controlled, double-blind studies with broader measures to clarify DMT's therapeutic profile and its possible integration into health systems.